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Uterine sarcomas account for approximately 1% of all female genital
tractmalignancies and 3%−7% of all uterine cancers [1]. Their rarity and
histopathological diversity have contributed to the lack of consensus on
risk factors for poor outcome and optimal treatment [2].
Histologically, uterine sarcomas were classiﬁed initially into
carcinosarcomas (malignant mesodermal mixed tumors), accounting
for 50% of cases, leiomyosarcomas (30%), endometrial stromal sarcomas
(15%), and undifferentiated sarcomas (5%). Subsequently, carcino-
sarcoma has been reclassiﬁed, largely based on its spreading pattern,
as a dedifferentiated or metaplastic form of endometrial carcinoma.
However, as it behaves more aggressively than the usual type of
endometrial carcinoma, carcinosarcoma is still included in most
retrospective studies of uterine sarcomas, as well as in the separate
section of “mixed epithelial and mesenchymal tumors” of the 2014
WHO classiﬁcation [3].
Tumor stage is the single most important prognostic factor. In the
past, uterine sarcomas were staged using a staging system proposed
in 1988 for endometrial carcinoma. This has not proven satisfactory
and, in 2009, a new FIGO staging system was developed for uterine
sarcomas (Table 1) [4]. The new staging system has two divisions, one
for leiomyosarcoma and endometrial stromal sarcoma (ESS), and one
for adenosarcoma. Carcinosarcoma is still staged using the endometrial
carcinoma staging system [4].
Prolonged use of tamoxifen, a uterine estrogen receptor agonist, is
associated with a three times risk of sarcoma development [5]. There
have been reported cases of radiation-induced sarcomas occurring
long after treatment for other cancers [6].
Neither preoperative imaging with ultrasonography nor PET scans
are capable of differentiating between benign or malignant smooth
muscle masses. The use of diffusion weighted magnetic resonance
imaging (DWI) for tumor location and characterization has been
suggested, but is yet to be validated.
Patients with carcinosarcomas and adenosarcomas tend to be much
older than patients with other sarcomas.2. Leiomyosarcomas
Leiomyosarcomas are considered true sarcomas.http://dx.doi.org/10.1016/j.ijgo.2015.06.006
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).2.1. Clinical features
After excluding carcinosarcoma, leiomyosarcoma has become the
most common subtype of uterine sarcoma even though it accounts for
only 1%−2% of uterine malignancies [2]. Approximately 1 in every 800
smooth muscle tumors of the uterus is a leiomyosarcoma [2]. It occurs
in women over 40 years of age who usually present with abnormal
vaginal bleeding (56%), a palpable pelvic mass (54%), and/or pelvic
pain (22%) [2]. Signs and symptoms resemble those of the far more
common leiomyoma and preoperative distinction between the two tu-
mors may be difﬁcult. Malignancy should be suspected by the presence
of tumor growth in postmenopausal women who are not using
hormonal replacement therapy, although it is rare for a leiomyosarcoma
to present as a rapidly growing tumor.2.2. Pathological features
Leiomyosarcomas are either single masses or, when associated with
leiomyomas, the largest mass. They are typically voluminous tumors
with a mean diameter of 10 cm (only 25% of cases measure less than
5 cm). The cut surface is typically soft, bulging, ﬂeshy, necrotic, hemor-
rhagic, and lacks the prominent whorled appearance of leiomyomas.
The histopathologic diagnosis of leiomyosarcoma is usually straightfor-
ward as most clinically malignant smooth muscle tumors of the uterus
exhibit the constellation of hypercellularity, severe nuclear atypia,
and high mitotic rate generally exceeding 15 mitotic ﬁgures per 10
high-power-ﬁelds (MF/10 HPF) (Fig. 1) [3]. Moreover, one or more
supportive clinicopathologic features such as peri- or postmenopausal
age, extrauterine extension, large size (over 10 cm), inﬁltrating border,
necrosis, and atypical mitotic ﬁgures are frequently present. However,
epithelioid and myxoid leiomyosarcomas are two rare variants that
may be difﬁcult to recognizemicroscopically as their pathologic features
differ from those of ordinary spindle cell leiomyosarcomas. In both
tumor types nuclear atypia is usually mild and the mitotic rate often
less than 3 MF/10 HPF [3]. Necrosis may be absent in epithelioid
leiomyosarcomas and myxoid leiomyosarcomas are often hypocellular.
In the absence of severe cytologic atypia and high mitotic activity, both
tumors are diagnosed as sarcomas based on their inﬁltrative borders.
Theminimal pathological criteria for the diagnosis of leiomyosarcoma
are more problematic and, in such cases, the differential diagnosisGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 1
FIGO staging for uterine sarcomas.
Stage Deﬁnition
Leiomyosarcomas and endometrial stromal sarcomas
I Tumor limited to uterus
IA Less than 5 cm
IB More than 5 cm
II Tumor extends beyond the uterus, within the pelvis
IIA Adnexal involvement
IIB Involvement of other pelvic tissues
III Tumor invades abdominal tissues (not just protruding into the abdomen).
IIIA One site
IIIB More than one site
IIIC Metastasis to pelvic and/or para-aortic lymph nodes
IV IVA Tumor invades bladder and/or rectum
IVB Distant metastasis
Adenosarcomas
I Tumor limited to uterus
IA Tumor limited to endometrium/endocervix with no myometrial invasion
IB Less than or equal to half myometrial invasion
IC More than half myometrial invasion
II Tumor extends to the pelvis
IIA Adnexal involvement
IIB Tumor extends to extrauterine pelvic tissue
III Tumor invades abdominal tissues (not just protruding into the abdomen).
IIIA One site
IIIB More than one site
IIIC Metastasis to pelvic and/or para-aortic lymph nodes
IV IVA Tumor invades bladder and/or rectum
IVB Distant metastasis
Carcinosarcomas
Carcinosarcomas should be staged as carcinomas of the endometrium.
Note: Simultaneous tumors of the uterine corpus and ovary/pelvis in association with
ovarian/pelvic endometriosis should be classiﬁed as independent primary tumors.
Fig. 1. Leiomyosarcoma.
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histologic features and unusual growth patterns (Boxes 1 and 2), but
also atypical smooth muscle tumors (so-called smooth muscle tumors
of uncertain malignant potential [STUMPs]) (Box 3). Application of
the WHO diagnostic criteria [3] has allowed distinguishing these
unusual histologic variants of leiomyoma frequently misdiagnosed as
“well-differentiated” or “low-grade” leiomyosarcomas in the past. In a
population-based study of uterine sarcomas from Norway [7], of 356
tumors classiﬁed initially as leiomyosarcomas, the diagnosis was
conﬁrmed in only 259 (73%) cases, whereas 97 (27%) were excluded
on review and reclassiﬁed, according to WHO criteria, as leiomyomas
or leiomyoma variantsBox 1
Leiomyoma variants that may mimic malignancy.
• Mitotically active leiomyoma
• Cellular leiomyoma
• Hemorrhagic leiomyoma and hormone-induced changes
• Leiomyoma with bizarre nuclei (atypical leiomyoma)
• Myxoid leiomyoma
• Epithelioid leiomyoma
• Leiomyoma with massive lymphoid infiltration
Box 2
Smooth muscle proliferations with unusual
growth patterns.
• Disseminated peritoneal leiomyomatosis
• Benign metastasizing leiomyoma
• Intravenous leiomyomatosis
• Lymphangioleiomyomatosis2.3. Immunohistochemistry and molecular biology
Leiomyosarcomas usually express smooth muscle markers such as
desmin, h-caldesmon, smooth muscle actin, and histone deacetylase 8
(HDCA8). However, epithelioid and myxoid leiomyosarcomas may
show lesser degrees of immunoreaction for these markers [3]. Also,
leiomyosarcomas are often immunoreactive for CD10 (mainly consid-
ered a marker of endometrial stromal differentiation) and epithelial
markers including keratin and EMA (the latter being more frequently
positive in the epithelioid variant) [3]. Conventional leiomyosarcomas
express estrogen receptors, progesterone receptors, and androgen
receptors in 30%−40% of cases. Whereas a variable proportion of uter-
ine leiomyosarcomas has been reported as being immunoreactive for
c-KIT, no c-KITmutations have been identiﬁed [3].
The levels of Ki67 are higher in uterine leiomyosarcomas compared
with benign smooth muscle tumors. Overexpression of p16 has been
described in uterine leiomyosarcomas and may prove to be a useful ad-
junct immunomarker for distinguishing between benign andmalignant
uterine smooth muscle tumors [8].The vast majority of uterine leiomyosarcomas are sporadic. Patients
with germlinemutations in fumarate hydratase are believed to be at in-
creased risk for developing uterine leiomyosarcomas as well as uterine
leiomyomas [9]. The oncogenic mechanisms underlying the develop-
ment of uterine leiomyosarcomas remain elusive. Overall, uterine
leiomyosarcoma is a genetically unstable tumor that demonstrates
complex structural chromosomal abnormalities and highly disturbed
gene regulation, which likely reﬂects the end-state of accumulation of
multiple genetic defects.
2.4. Prognosis
Leiomyosarcomas diagnosed according to the WHO criteria [3] are
associated with poor prognosis even when conﬁned to the uterus at
the time of diagnosis [7,10]. Recurrence rate ranges from 53% to 71%
[11,12]. First recurrences occur in the lungs in 40% of patients and in
the pelvis in only 13% [13]. Overall ﬁve-year survival rate ranges from
15% to 25% with a median survival of only 10 months in one study
[14]. In the Norwegian series, 148 patients with leiomyosarcomas limit-
ed to the uterus had a ﬁve-year survival of 51% at Stage I and 25% at
Stage II (by the 1988 FIGO staging classiﬁcation). All patients with
tumor spread outside the pelvis died within 5 years [7].
Box 3
Atypical smooth muscle tumors (so-called smooth muscle tumors of
uncertain malignant potential [STUMP]).
• Tumor cell necrosis in a typical leiomyoma
• Necrosis of uncertain type with≥10 MF/10 HPFs, or marked
diffuse atypia
• Marked diffuse or focal atypia with borderline mitotic counts
• Necrosis difficult to classify
Fig. 2. Low-grade endometrial stromal sarcoma.
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correlation between survival and patient age, clinical stage, tumor
size, type of border (pushing versus inﬁltrative), presence or absence
of necrosis, mitotic rate, degree of nuclear pleomorphism, and vascular
invasion [3]. However, one study [15], found tumor size to be a major
prognostic parameter: 5 of 8 patients with tumors less than 5 cm in di-
ameter survived, whereas all patients with tumors greater than 5 cm in
diameter died. In a series of 208 uterine leiomyosarcomas [2], the only
other parameters predictive of prognosis were tumor grade and stage.
In the report fromNorway [7], including 245 leiomyosarcomas conﬁned
to the uterus, tumor size and mitotic index were signiﬁcant prognostic
factors and allowed for separation of patients into three risk groups
with marked differences in prognosis.
Ancillary parameters including p53, p16, Ki 67, and Bcl-2 have been
used in leiomyosarcomas to try to predict outcome [10]. It is not clear
whether they act independently of stage. However, a recent study
revealed that the combination of tumor size, mitotic index, Ki67, and
Bcl-2 protein expression allows two groups of leiomyosarcomas to be
distinguished, with different survival: tumors greater than or equal
to10 cm in diameter, with greater than or equal to 20MF/10 HPF, great-
er than or equal to10% immunoreactive nuclei for Ki67, and negative for
Bcl-2 hadworse prognosis than smaller leiomyosarcomaswith less than
or equal to 20 MF/10 HPF, less than or equal to10% immunoreactive
nuclei for Ki67, and positive or negative for Bcl-2 [15].
2.5. Treatment
Treatment of leiomyosarcomas includes total abdominal hysterecto-
my and debulking of the tumor if present outside the uterus. Removal of
the ovaries and lymphnode dissection remain controversial asmetasta-
ses to these organs occur in only a small percentage of cases and are
frequently associated with intra-abdominal disease [2]. Ovarian preser-
vation may be considered in premenopausal patients with early-stage
leiomyosarcomas [2]. Lymph node metastases have been identiﬁed in
6.6% and 11% in two series of patients with leiomyosarcoma who
underwent lymphadenectomy [2,16]. In the ﬁrst series, the ﬁve-year
disease-speciﬁc survival rate was 26% in patients who had positive
lymph nodes compared with 64.2% in patients who had negative
lymph nodes (P b 0.001) [16]. The inﬂuence of adjuvant therapy on sur-
vival is uncertain. Radiotherapymay be useful in controlling local recur-
rences and chemotherapywith doxorubicin or docetaxel/gemcitabine is
nowused for advanced or recurrent diseasewith response rates ranging
from27% to36% [17]. Some tumorsmay respond to hormonal treatment
[18]. Targeted therapies such as trabectedin have been investigated as
treatment in advanced stage or metastatic leiomyosarcoma with some
appreciable disease control [19].
3. Atypical smooth muscle tumors (smooth muscle tumors of
uncertain malignant potential) (STUMP)
Uterine smoothmuscle tumors that show someworrisomehistolog-
ical features (i.e. necrosis, nuclear atypia, or mitoses), but do not
meet all diagnostic criteria for leiomyosarcoma, fall into the category
of atypical smooth muscle tumors (STUMP) (Box 2) [3]. This diagnosis,
however, should be used sparingly and every effort should be made toclassify a smooth muscle tumor into a speciﬁc category when possible
[3]. Most tumors classiﬁed as atypical smooth muscle tumors
(STUMP) have been associated with favorable prognosis and, in these
cases, only follow-up of the patients is recommended.
4. Endometrial stromal tumors
Endometrial stromal tumors account for less than 1% of all uterine
tumors [1]; nevertheless, they represent the second most common
category of mesenchymal uterine tumors. They are predominantly or
exclusively intramural neoplasms and are divided into benign and ma-
lignant based on the type of tumor margin: well-circumscribed tumors
are benign stromal nodules, whereas those exhibiting myometrial
invasion and permeation of myometrial lymphovascular spaces are sar-
comas [3]. Endometrial sarcomas are further classiﬁed by the latest
WHO classiﬁcation, based on resemblance to (or lack of) proliferative-
type endometrial stroma, into the following three main categories:
(1) low-grade endometrial stromal sarcoma; (2) high-grade endometri-
al stromal sarcoma; and (3) undifferentiated endometrial sarcoma [3].
4.1. Low-grade endometrial stromal sarcoma
Low-grade endometrial stromal sarcomas frequently occur in
women between 40 and 55 years of age and more than 50% of patients
are premenopausal [19]. Some cases have been reported inwomenwith
ovarian polycystic disease, and after estrogen use or tamoxifen therapy
[19]. Patients commonly presentwith abnormal uterine bleeding, pelvic
pain, and dysmenorrhea, but as many as 25% are asymptomatic [15]. At
presentation, extrauterine pelvic extension, most commonly involving
the ovary, is found in up to one-third of patients [19,20].
Microscopically, endometrial stromal sarcomas consist of well-
differentiated endometrial stromal cells exhibiting only mild nuclear
atypia and characteristically invade the lymphovascular spaces of the
myometrium (Fig. 2). Tumor cell necrosis is rarely seen.
The tumor cells are strongly immunoreactive for CD10, usually
positive for smooth-muscle actin and less frequently for desmin (30%),
but they are negative for h-caldesmon and HDAC8. Estrogen receptors
(only alpha isoform), progesterone receptors, androgen receptors, and
WT-1 are typically positive. Nuclear beta-catenin expression has been
shown in up to 40% of low-grade endometrial stromal sarcomas. The
most common cytogenetic abnormality of low-grade endometrial stro-
mal sarcomas is a recurrent translocation involving chromosomes 7 and
17 t(7;17)(p15;q21)], which results in a fusion between JAZF1 and
SUZ12 (formerly designated as JJAZ1) [21]. The fusion can be detected
by ﬂuorescence in situ hybridization as well as by reverse transcriptase–
polymerase chain reaction.
Fig. 3. Adenosarcoma.
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a favorable prognosis [19]. Tumor behavior is characterized by late
recurrences even in patients with Stage I disease; thus, long-term
follow-up is required. About one-third of patients develop recurrences,
most commonly in the pelvis and abdomen, and less frequently in the
lungs and vagina [19]. Stage of the tumor is the most signiﬁcant prog-
nostic factor. Surgical stage higher than Stage I is a univariate predictor
of unfavorable outcome. Five-year survival for patientswith Stages I and
II tumors is 90% compared with 50% for Stages III and IV [22].
Treatment of low-grade endometrial stromal sarcomas is largely sur-
gical in the form of hysterectomy and bilateral salpingo-oophorectomy.
The tumors are often sensitive to hormones and it has been shown that
patients retaining their ovaries have a much higher risk of recurrence
(up to 100%) [23]. Lymph node dissection does not seem to have a
role in the treatment of these tumors. Patients may also receive adju-
vant radiation or hormonal treatment with progestational agents or
aromatase inhibitors. Hormone replacement therapy is discouraged.
4.2. High-grade endometrial stromal sarcoma
These rare tumors have features that are intermediate between low-
grade endometrial stromal sarcomas and undifferentiated sarcomas
[24]. Patients range in age from 28–67 years (mean 50 years) and usu-
ally present with abnormal vaginal bleeding, an enlarged uterus, or a
pelvic mass [25].
The tumors may appear as intracavitary polypoid or mural masses.
They range in size up to 9 cm (median 7.5 cm) and often show extra-
uterine extension at the time of diagnosis. The cut surface is ﬂeshy
with extensive areas of necrosis and hemorrhage. Microscopically,
they consist predominantly of high-grade round-cells that are some-
times associated with a low-grade spindle cell component that is most
commonly ﬁbromyxoid [25]. Mitotic activity is striking and typically
greater than 10 per 10 HPF. Necrosis is usually present. Rarely, areas of
conventional low-grade endometrial stromal sarcoma are seen. High-
grade endometrial stromal sarcomas are CD10, estrogen receptor, and
progesterone receptor negative but show strong diffuse cyclin D1 im-
munoreactivity (N70% nuclei). They are also typically c-Kit positive but
DOG1 negative. High-grade endometrial stromal sarcoma typically har-
bors the YWHAE-FAM22 genetic fusion as a result of t(10;17) (q22;p13).
These tumors appear to have a prognosis that is intermediate, be-
tween low-grade endometrial stromal sarcomas and undifferentiated
uterine sarcomas [25]. Compared with low-grade endometrial stromal
sarcomas, patients with high-grade endometrial stromal sarcomas
have earlier and more frequent recurrences (often b1 year) and are
more likely to die of disease. Advanced or recurrent tumors (10;17)
should be treated aggressively with a combination of radiation and
chemotherapy as they do not respond to conventional treatment for
low-grade endometrial stromal sarcomas [25].
4.3. Undifferentiated endometrial sarcoma
This tumor is rare. Patients are typically postmenopausal (mean age
is 60 years) and have postmenopausal bleeding or signs/symptoms
secondary to extra-uterine spread [26]. Approximately 60% of patients
present with high-stage disease (Stage III/IV). The diagnosis of un-
differentiated endometrial sarcoma is applied to tumors that exhibit
myometrial invasion, severe nuclear pleomorphism, high mitotic activ-
ity and/or tumor cell necrosis, and lack smooth muscle or endometrial
stromal differentiation [3]. The histological appearance of this tumor is
more like themesenchymal elements of a carcinosarcoma than a typical
endometrial stromal tumor. It is variably CD10 positive and typically
estrogen receptor and progesterone weakly positive or negative.
Undifferentiated endometrial sarcomas are highly aggressive tumors
that are associatedwith a very poor prognosis (less than 2 years’ surviv-
al) [26]. Patients should be treated by hysterectomy and bilateral
salpingo-oophorectomy and adjuvant radiation and/or chemotherapy.5. Adenosarcoma
Müllerian adenosarcoma is amixed tumor of lowmalignant potential
that shows an intimate admixture of benign glandular epithelium and
low-grade sarcoma, usually of endometrial stromal type. It represents
between 5% and 10% of all uterine sarcomas. The tumor occurs mainly
in the uterus of postmenopausal women (average 58 years) but also in
adolescents and young adults (30%) [27]. Most adenosarcomas arise
from the endometrium, including the lower uterine segment, but rare
tumors develop in the endocervix (5%−10% of cases) and in extrauterine
locations [28].
Adenosarcomas are polypoid tumors of approximately 5–6 cm
in maximum diameter (range, 1–20 cm) that typically ﬁll and
distend the uterine cavity. Adenosarcomas with sarcomatous
overgrowth tend to be larger with a ﬂeshy, hemorrhagic, and necrot-
ic cut surface. They invade the myometrium more often than
conventional adenosarcomas.
Microscopically, the stroma typically concentrates around the
glands forming periglandular cuffs (Fig. 3). Well-differentiated tumors
may exhibit only mild nuclear atypia and very few or no mitoses in
the stromal component. However, the presence of hypercellular
periglandular cuffs helps to distinguish adenosarcoma from its rarer be-
nign counterpart, the adenoﬁbroma [28]. Heterologous mesenchymal
elements, usually rhabdomyosarcoma, are found in 10%−15% of cases.
Vaginal or pelvic recurrence occurs in approximately 25%−30% of
cases at 5 years and is associated almost exclusively with myometrial
invasion and sarcomatous overgrowth [27,28]. Myometrial invasion is
found in approximately 15% of cases, but deep invasion in only 5% [27,
28]. Sarcomatous overgrowth, deﬁned as the presence of pure sarcoma,
usually of high-grade andwithout a glandular component, occupying at
least 25% of the tumor, has been reported in 8% to 54% of uterine
adenosarcomas [27,28].
Whereas immunoreactions for cell proliferation markers (Ki-67
and P53) are stronger in adenosarcomas with sarcomatous overgrowth
than in typical adenosarcomas, the expression of markers of cell differ-
entiation (CD10 and PR) is higher in typical adenosarcomas than in
adenosarcomas with sarcomatous overgrowth [28].
Except when associated with myometrial invasion or sarcomatous
overgrowth, the prognosis of adenosarcoma is far more favorable
than that of carcinosarcoma; however, about 25% of patients with
adenosarcoma ultimately die of their disease [27]. Recurrences are
usually composed exclusively of mesenchymal elements. Distant
metastases, which occur in 5% of cases, are almost always composed
of pure sarcoma (70%). The treatment of choice is total abdominal
hysterectomy with bilateral salpingo-oophorectomy.
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Carcinosarcoma, also referred to as “malignant müllerian mixed
tumor,” is a biphasic neoplasm composed of distinctive and separate,
but admixed, malignant-appearing epithelial and mesenchymal
elements (Fig. 4). The mean age of patients with carcinosarcoma is in
the seventh decade, but the age range spans from the fourth through
the ninth decades [29]. The disease usually presents like other endome-
trial cancers with vaginal bleeding. Another typical presentation of
carcinosarcoma is in the formof a polypoidmass that protrudes through
the cervical os.
The epithelial component is serous, or high-grade carcinoma not
otherwise speciﬁed, in about two-thirds of cases, and endometrioid
carcinoma in approximately one-third [29]. In a recent study, 10% of
the carcinomatous components were FIGO grade 1, 10% grade 2, and
80% grade 3 [29]. The homologous components of carcinosarcoma
are usually spindle cell sarcoma without obvious differentiation;
many resemble ﬁbrosarcomas or pleomorphic sarcomas. Almost all
are high-grade sarcomas. The most common heterologous elements
are malignant cartilage or skeletal muscle constituting something
that resembles either pleomorphic rhabdomyosarcoma or embryonal
rhabdomyosarcoma [1].
Carcinosarcomas are highly aggressive tumors—far more aggressive
than usual endometrial carcinomas. The overall ﬁve-year survival for
patients with carcinosarcoma is around 30% and for those with Stage I
disease (conﬁned to the uterus) it is approximately 50% [1,6,30,31].
This is in contrast with other high-grade endometrial cancers for
which ﬁve-year survival in Stage I disease is approximately 80% or
higher [32,33]. This has led to toxic treatment protocols that usually
include ifosfamide and cisplatin along with whole pelvic irradiation.
In carcinosarcomas, there is general agreement that surgical stage is
the most important prognostic indicator regardless of how the patient
was staged. A recent study found that the presence of heterologous
elements is a poor prognostic factor in patientswith FIGO Stage I tumors
[29]. Other factors proposed include the histologic grade of the
carcinomatous and sarcomatous elements, the percentage of tumor
with sarcomatous differentiation, depth of myometrial invasion, and
presence of lymphovascular invasion [1,6,30,31].
6.1. Treatment of carcinosarcomas
Primary surgery for early disease includes a hysterectomy, bilateral
salpingo-oophorectomy, and pelvic node dissection as the tumor spread
pattern is similar to high-grade endometrial carcinomas. Omentectomy
is also advocated by some. Complete cytoreduction should be the aim of
surgery, as this may be associated with an overall survival beneﬁt.Fig. 4. Carcinosarcoma.Combination chemotherapy seems to result in fewer recurrences
than whole body irradiation [34]. Patients with carcinosarcomas,
however, tend to be elderly with co-morbidities. The ideal agents
still need to be established. The results of the Gynecologic Oncology
Group 261 study, which aims to compare ifosfamide/paclitaxel versus
carboplatin/paclitaxel combinations in patients with advanced stage
or recurrent carcinosarcoma, are awaited. Radiotherapy is only able to
control pelvic disease [35].
6.2. Follow-up of sarcomas
Follow-up should be determined by risk of recurrence. Asmetastasis
to the lungs is common, efforts must be made to rule these out
remembering that early lesions tend to be asymptomatic but resectable.
Low-grade sarcoma patients may be followed for local relapse every 4–
6 months for the ﬁrst 3–5 years, then yearly. High-grade tumors can be
followed-up every 3–4 months for the ﬁrst 2–3 years, twice a year for
the next 2–3 years, and then annually.
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